Matrifen® for Therapy of Severe Chronic Pain®

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nycomed
• Treatments: Fentanyl

Criteria

Main inclusion criteria:

• Outpatients with severe, chronic pain

Main exclusion criteria:

• Hypersensitivity to fentanyl

• Co-administration of monoamineoxidase-inhibitors

• Pregnancy

• Respiratory depression

• Chronic obstructive pulmonary disease (COPD)

• Drug abuse

• Impairment of CNS functions

• Other criteria as defined in the Summary of Product Characteristics (Chapter 4.3)